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Neural degeneration in glaucoma involves retinal ganglion cells and neurons of their major target, the
lateral geniculate nucleus (LGN). Dendrites of relay LGN neurons projecting to the visual cortex were
studied by immunocytochemical and quantitative Sholl analysis in combination with confocal micros-
copy and 3D-morphometry. In non-human adult primate glaucoma, relay LGN neurons showed reduced
dendrite complexity and length, and these changes were modiﬁed by NMDA receptor blockade. Dendrite
plasticity of LGN relay neurons in adult primate glaucoma has implications for potential disease modiﬁ-
cation by treatment interventions.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Glaucoma is a major cause of irreversible blindness world-
wide, characterized by retinal ganglion cell (RGC) loss (Weinreb
& Khaw, 2004). Degeneration of retinal ganglion cells spreads
trans synaptically to their main target, the lateral geniculate nu-
cleus (LGN) of the brain in human glaucoma (Gupta, Ang, Noel
de Tilly, Bidaisee, & Yucel, 2006; Gupta et al., 2009). Previous
studies in experimental primate glaucoma, show degenerative
changes in the LGN including neuron loss (Weber, Chen, Hub-
bard, & Kaufman, 2000; Yucel, Zhang, Gupta, Kaufman, & Wein-
reb, 2000), neuron atrophy (Weber et al., 2000; Yucel, Zhang,
Weinreb, Kaufman, & Gupta, 2001), reactive gliosis (Sasaoka
et al., 2008), and microglial activation (Imamura et al., 2009).
Neuron loss and atrophy increase with increasing RGC loss as
do metabolic changes observed in the visual cortex in primate
glaucoma. (Yucel, Zhang, Weinreb, Kaufman, & Gupta, 2003;
Yucel et al., 2000, 2001).
Dendrites are ﬁne processes emerging from the cell body of
neurons that form elaborate dendritic arbors supporting post-syn-
aptic contact elements (Johnston & Narayanan, 2008). Distur-
bances to dendrite branching can disrupt neural network
organization and lead to neural dysfunction, as in human neurolog-ll rights reserved.
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l).ical disorders including Alzheimer’s disease (Moolman, Vitolo,
Vonsattel, & Shelanski, 2004). Their ﬁne structure is maintained
by microtubules, and among the associated proteins, microtu-
bule-associated protein-2 (MAP2) is enriched in dendrites (Cassim-
eris & Spittle, 2001; Ichihara, Kitazawa, Iguchi, Hotani, & Itoh,
2001) playing an important role in dendrite morphology and
branching (Dehmelt & Halpain, 2005; Harada, Teng, Takei, Oguchi,
& Hirokawa, 2002; Matus, 1994). MAP2 has been used as a marker
to assess dendrites in neurodegenerative diseases (Goedert,
Crowther, & Garner, 1991; Kaufmann, Naidu, & Budden, 1995;
Kwei, Jiang, & Haddad, 1993; Matesic & Lin, 1994).
In glaucoma, dendrites in the primate retina undergo atrophy
(Morgan, Uchida, & Caprioli, 2000; Weber, Kaufman, & Hubbard,
1998). A study in which LGN interneurons conﬁned to the LGN
and relay neurons projecting to the visual cortex were not dis-
criminated, showed dendrite changes in primate glaucoma (Gup-
ta et al., 2007). However, detailed dendrite evaluation of the LGN
relay neurons under conditions of glaucoma at various stages of
disease and following pharmacological treatment has not been
previously investigated. Memantine is an NMDA glutamate
open-channel blocker approved as a neuroprotective agent for
the treatment of cognitive impairment in Alzheimer’s disease
(Reisberg et al., 2003). The purpose of this work is to identify
and quantify dendrite characteristics of LGN relay neurons in a
primate model of glaucoma to determine whether they are al-
tered, and if so, whether these changes are modiﬁable by
memantine (Bormann, 1989).
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2.1. Subjects
All experiments were performed following the guidelines of the
Association for Research in Vision and Ophthalmology Resolution
on the Use of Animals in Research.
Six LGNs from six normal adult cynomolgusmonkeys (Macaca fas-
cicularis) fromtheUniversityofWisconsin,Madisonwereusedas con-
trols. Theywere perfused intracardiallywith 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4). Intraocular pressure (IOP) measure-
ments were performed in vivo before sacriﬁce with a pneumatonom-
eter (Digilab, Norwell, MA) under light sedation (intramuscular
injection of 5 mg/kg of ketamine hydrochloride) and topical anesthe-
sia (5% proparacaine hydrochloride) (Yucel et al., 2000). Themean IOP
ranged from 12.3 to 21.0 mmHg and themaximum IOP ranged from
13.0 to 26.0 mm Hg. There was signiﬁcant difference in mean IOP
(P < 0.001) or maximum IOP (P < 0.001) between the vehicle-treated
glaucoma group and the normal group.
Experimental glaucoma was induced in adult monkeys (Macaca
fascicularis) by laser scariﬁcation of the trabecular meshwork (Hare
et al., 2004). The duration of IOP elevation was 14 months. Three
animals out of 18 were excluded from the present study due to
either suboptimal ﬁxation or unidentiﬁable LGN layers. Two
groups of monkeys were evaluated and compared: (1) seven vehi-
cle-treated (VT) monkeys with glaucoma and (2) eight memantine-
treated (MT) monkeys with glaucoma who received a daily oral
dose of 4 mg/kg of memantine. In both the VT and MT glaucoma
groups, the treatment was continued during 14 months until sacri-
ﬁce (Hare et al., 2004). There was no signiﬁcant difference in mean
IOP (P = 0.43) or maximum IOP (P = 0.73) between the VT and MT
glaucoma groups (Yucel, Gupta, Zhang, Mizisin, Kalichman, &
Weinreb, 2006). Previously published optic nerve counts of these
animals showed no signiﬁcant difference in mean percent optic
nerve ﬁber loss between the VT and the MT glaucoma groups
(Yucel, Gupta et al., 2006).2.2. Tissue processing
Perfusion ﬁxation under deep general anesthesia and tissue
processing and 40 lm-thick serial sections were performed (Yucel
et al., 2000). Every seventh section was mounted onto a glass slide
and stained with cresyl violet. Care was taken to use the same tis-
sue processing procedures for all monkey brains. Sections contain-
ing left LGN with six layers were randomly selected for each of the
normal control animals and each of the VT and MT glaucoma
animals.2.3. Double immunoﬂuorescence labeling of MAP2 and parvalbumin
LGN sections were double-labeled with a monoclonal antibody
against MAP2 (Clone HM-2, Sigma, St. Louis, MO), and a polyclonal
antibody against parvalbumin (PV28, Swant, Bellinzona, Switzer-
land), a calcium-binding protein, a speciﬁc marker for relay LGN
neurons (Johnson & Casagrande, 1995). The tyramide signal ampli-
ﬁcation (TSA) kit (Invitrogen Inc., ON, Canada) was used to enhance
immunostaining. Sections were washed with phosphate buffered
saline (1  PBS, 3  10 min). All subsequent washes were per-
formed with 1  PBS, pH 7.35 (3  5 min). Sections were incubated
with 0.2% Triton-X (Sigma, St. Louis, MO) in PBS (2  5 min). After
PBS wash, endogenous peroxidase activity was quenched by 3%
H2O2 (2  15 min). Sections were washed with PBS and blocked
in 1% blocking reagent (TSA kit). Incubation in parvalbumin
[1:500] was extended to 2 h at room temperature, overnight at
4 C and then left at room temperature for another 2 h. Sectionswere washed with PBS and incubated in anti Rabbit-HRP [1:100]
(TSA kit). After PBS wash, sections were incubated in Tyramide-
Alexa Fluor-488 diluted in Ampliﬁcation Buffer [1:100]
(2  10 min). Sections were washed with PBS, quenched with 3%
H2O2 (2  15 min), and blocked in 1% blocking reagent. Incubation
in MAP2 [1:100] was extended to 2 h at room temperature, over-
night at 4 C and then left at room temperature for another 2 h.
Sections were washed with PBS and incubated in anti Mouse-
HRP [1:100] (TSA kit). After being washed again in PBS, sections
were incubated in Tyramide-Alexa Fluor-555 [1:100]
(2  10 min) diluted in Ampliﬁcation buffer (TSA kit). Sections
were washed again with PBS, mounted with antifade PVA-DABCO
onto Vectabond (Vector Laboratories, Burlingame, CA) coated
slides and cover-slipped. Immunostaining experiments for all three
groups were performed simultaneously with same reagents. Nega-
tive controls were obtained by omitting the primary antibodies.
2.4. Morphological assessment
Immunoﬂuorescence-labeled sections were viewed using an
Olympus bright ﬁeld BX51 upright microscope with a color digital
camera (Microﬁre, Optronics Inc. Goleta, CA) and a computer mon-
itor. The LGN layers were identiﬁed as layers 1–6 from ventral to
dorsal. The ventral layers 1 and 2 are magnocellular layers, while
the remaining dorsal layers 3–6 are parvocellular layers. Layers
1, 4 and 6 of the left LGN are connected to the glaucomatous right
eye while layers 2, 3 and 5 are connected to the non-glaucomatous
left eye. We analyzed MAP2-immunoreactive dendrites of parval-
bumin-positive relay neurons projecting to the primary visual cor-
tex (Johnson & Casagrande, 1995), located in left LGN
magnocellular layer 1 and parvocellular layer 6 connected to the
glaucomatous right eye.
2.5. Quantitative analysis
2.5.1. Confocal image acquisition
Sections fromMT and VT glaucoma groups, and normal controls
were examined using LaserSharp 2000 software (Biorad Cell Sci-
ence Division, Hernelhempstead, UK) with a digital camera on an
upright confocal laser microscope (Biorad Radiance, Bronx, NY on
Nikon E800 Upright Microscope, Melville, NY) in a masked fashion.
Five sampling sites of 500 lm  500 lm within each magnocellu-
lar layer 1 and parvocellular layer 6 were selected. Within each
sampling site, one stack of images was taken under red (CY3 for
MAP2) and green (FITC for parvalbumin) channels separately with
a 60 oil-immersion objective at zoom of 1.5 and 512  512 pix-
els by LaserSharp2000 program. Serial stack images of 18 lm
depth and 0.5 lm step size were collected using the same camera
settings for power, gain, iris aperture size, and offset to maintain
consistent settings for comparison. All images were obtained using
a Kalman ﬁlter with three passes.
2.5.2. Automated tracing and 3D reconstruction
Stacks of images were imported (Neurolucida; MicroBright-
Field, Inc., Colchester, VT) and neurons were traced with an auto-
mated tracing software (AutoNeuron, MicroBrightField Inc.,
Colchester, VT). Tracing of MAP2-immunoreactive dendrites (CY3
channel) and parvalbumin-immunostained cell bodies (FITC chan-
nel) of stacks of confocal images was performed separately. Two
modes of the automated tracing software were used to trace neu-
rons: interactive mode for MAP2-immunostained dendrites, and
automatic mode for parvalbumin-immunostained cell bodies. Con-
ﬁguration parameters used for tracing for each neuron were: (1)
maximum process diameter, 1.5 lm, (2) ignore somas smaller
than, 2.0 lm, (3) soma detector sensitivity, 55 and 65 for layers 1
and 6, respectively, and (4) interactive mode.
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Immunoﬂuorescence labeling, image acquisition and quantita-
tive analysis of the dendrites were performed in a masked fashion.
Tracings were loaded into Neurolucida software (NeuroExplorer,
MicroBrightField Inc. VT, USA). A total of 45 parvalbumin-positive
neurons with MAP2-immunostained dendrites were selected ran-
domly from each magnocellular layer 1 and parvocellular layer 6
per animal for dendrite complexity analysis (Sholl analysis, Neu-
roExplorer) and dendrite length analysis (Branch Structure Analy-
sis, NeuroExplorer). In Sholl analysis, once the cell body to study
was selected, the intersections of dendrites and series of spheres
with radii 1–14 lm, spaced at 1-lm increments, were generated
by the software around the cell body. The number of dendrite-
sphere intersections to estimate dendrite complexity was calcu-
lated by the software. The percent decrease in dendrite complexity
was calculated from the difference between the average mean den-
drite complexity of the normal group and mean dendrite complex-
ity of MT and VT animals with glaucoma divided by the average
mean of dendrite complexity in the normal group. Percent de-
crease in dendrite length was assessed in a similar manner.2.6. Statistical analysis
The two-tailed student t-test was used to compare dendrite
parameters in relay neurons in LGN layers 1 and 6 of the VT glau-
coma group to the MT glaucoma group, and to the normal control
group. Mean IOP, maximum IOP, and percent optic nerve ﬁber loss
were also compared using a t-test.
Using the generalized linear models procedure of SAS statistical
software (SAS Institute Inc., Cary, NC), percent decrease in dendrite
complexity and dendrite length were compared between the
memantine- and the vehicle-treated glaucoma groups, with mean
IOP as a covariate.Fig. 1. Projected images of stacks of confocal images of LGN relay neurons immunostaine
in magnocellular layer 1 from normal monkey ID #S1, from vehicle-treated (VT) glau
respectively (Table 1). MAP2 immunoreactivity in normal layer 1 (A) was more intense c
MAP2 appeared more intense in MT glaucoma (C) compared to VT glaucoma monkeys (B
and MT glaucoma (F) monkeys. Scale bar indicates 40 lm.3. Results
3.1. Dendritic plasticity in LGN relay neurons in experimental
glaucoma (Fig. 1)
MAP2-immunoreactivity in magnocellular layer 1 relay neurons
in normal monkey (Fig. 1A) was more intense compared to vehicle-
treated (VT) glaucoma monkeys (Fig. 1B). Similar observations
were made for parvocellular layer 6 (Fig. 1D and E). MAP2-immu-
noreactivity in magnocellular layer 1 relay neurons in memantine-
treated (MT) glaucoma monkeys (Fig. 1C) was more intense
compared to VT glaucoma monkeys (Fig. 1B). Similar observations
were made for parvocellular layer 6 (Fig. 1E and F).
Dendrite complexity (Fig. 2) and length weremeasured in normal
group,VTandMTglaucomagroups (Table1). Inmagnocellular layer1,
bothmean dendrite complexity (Fig. 3A) and dendrite length (Fig. 3B)
weresigniﬁcantlydecreased intheVTglaucomagroupcomparedwith
those in the normal group (11.2 ± 1.0 (Mean ± SD) vs. 23.7 ± 1.5,
P < 0.0001; 18.4 ± 1.4 lmvs. 38.5 ± 3.1 lm, P < 0.0001; respectively).
In parvocellular layer 6, both mean dendrite complexity (Fig. 4A)
and length (Fig. 4B) were signiﬁcantly decreased in the VT glaucoma
group compared with those in the normal group (11.1 ± 1.3 vs.
21.2 ± 0.9, P < 0.0001; 16.7 ± 1.9 lm vs. 33.7 ± 2.4 lm, P < 0.0001,
respectively).3.2. Dendritic alterations in LGN relay neurons in memantine-treated
glaucoma monkeys
3.2.1. Magnocellular layer 1
Percent decrease in dendrite complexity (Table 2) in MT glau-
coma was signiﬁcantly reduced compared to VT glaucoma group
(38.1% ± 10.7 vs. 52.9% ± 4.2, P = 0.0047; respectively). Percentd with parvalbumin (green) and dendrites with MAP2 (red). A, B and C show neurons
coma monkey #106 and from memantine-treated (MT) glaucoma monkey #97,
ompared to those in the VT glaucoma (B) and MT glaucoma (C) monkeys. In layer 1,
). Similar results were seen in parvocellular layer 6 in normal (D), VT glaucoma (E)
Fig. 2. A randomly selected parvalbumin-positive neuron with MAP2-positive
dendrites selected from layer 6 from normal monkey S1 for dendritic complexity
analysis is shown. Concentric spheres with different radii (1–11 lm) with intervals
of 0.5 lm are placed on the cell and its dendrites. The intersections between these
circles and dendrites are used to analyze the complexity of dendritic arborization
(Sholl analysis, Neuroexplorer, Colchester, VT).
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reduced compared to VT glaucoma (Table 2).Table 1
Dendritic parameters of LGN relay neurons in normal monkeys, and veh
monkeys.
Group, ID Dendrite complexity, mean ± SD
Layer 1 Layer 6
Normal
S1 22.3 ± 4.1 22.8 ± 5.7
S2 22.9 ± 4.9 21.6 ± 4.7
S4 22.7 ± 4.3 20.2 ± 3.8
S6 26.2 ± 6.2 20.6 ± 4.4
S7 23.2 ± 4.8 20.8 ± 5.6
S10 24.9 ± 4.7 21.3 ± 4.6
Mean ± SD 23.7 ± 1.5 21.2 ± 0.9
Vehicle-treated glaucoma
91 11.4 ± 4.7 10.9 ± 4.4
92 9.5 ± 3.1 9.5 ± 2.9
93 10.6 ± 3.2 9.4 ± 2.8
96 10.5 ± 4.2 10.7 ± 3.0
98 11.7 ± 4.5 12.4 ± 4.5
105 12.2 ± 5.2 11.7 ± 4.1
106 12.2 ± 4.6 12.8 ± 4.2
Mean ± SD 11.2 ± 1.0 11.1 ± 1.3
P valuea <0.0001 <0.0001
Memantine-treated glaucoma
94 18.2 ± 6.2 14.6 ± 6.0
95 12.0 ± 3.3 12.6 ± 3.6
97 15.6 ± 6.9 14.5 ± 4.7
99 16.4 ± 6.3 15.2 ± 5.1
100 13.4 ± 3.6 12.8 ± 3.5
101 10.6 ± 3.7 12.5 ± 3.4
102 16.6 ± 7.7 16.5 ± 5.7
107 14.5 ± 5.7 13.6 ± 6.0
Mean ± SD 14.7 ± 2.5 14.0 ± 1.4
P valueb 0.0048 0.0011
SD = Standard deviation.
a t-Test values for comparison between VT glaucoma group and no
b t-Test values for comparison between MT and VT glaucoma grou3.2.2. Parvocellular layer 6
Percent decrease in dendrite complexity (Table 2) in MT glau-
coma was signiﬁcantly reduced compared to VT glaucoma group
(33.8% ± 6.7 vs. 47.8% ± 6.3, P = 0.0011). Percent decrease in den-
drite length in MT glaucoma was also signiﬁcantly reduced com-
pared to VT glaucoma (Table 2).
3.3. Relation with dendritic changes and mean IOP in memantine-
treated and vehicle-treated glaucoma groups
3.3.1. Magnocellular Layer 1
Percent decrease in mean dendrite complexity increased with
mean IOP for magnocellular layer (Fig. 5A) for MT and VT glaucoma
groups, and the linear regression of the dendrite complexity de-
crease on IOP was statistically signiﬁcant (P < 0.05). ANCOVA test,
with mean IOP as a covariate, showed signiﬁcantly less percent de-
crease in dendrite complexity in the MT glaucoma group compared
to the VT glaucoma group (P = 0.017).
The linear regression of the dendrite length decrease on IOP was
statistically signiﬁcant (Fig. 5B) (P < 0.05). ANCOVA test, with mean
IOP as a covariate, showed signiﬁcantly less percent decrease in
dendrite dendrite length in the MT compared to the VT group in
magnocellular layer 1 (P = 0.0032).
3.3.2. Parvocellular layer 6
Percent decrease in mean dendrite complexity increased with
mean IOP for parvocellular layer 6 (Fig. 6A) for MT and VT glau-
coma groups, and the linear regression of the dendrite complexity
decrease on IOP was statistically signiﬁcant (P < 0.05). ANCOVA
test, with mean IOP as a covariate, showed signiﬁcantly less per-
cent decrease in dendrite complexity in the MT compared to theicle-treated (VT) glaucoma and memantine-treated (MT) glaucoma
Total dendrite length (urn), mean ± SD
Layer 1 Layer 6
35.1 ± 6.7 36.4 ± 9.1
38.5 ± 8.0 31.1 ± 7.4
37.0 ± 7.2 33.0 ± 6.9
43.1 ± 10.7 32.7 ± 6.5
36.2 ± 7.3 37.0 ± 9.1
41.1 ± 8.3 32.2 ± 7.7
38.5 ± 3.1 33.7 ± 2.4
18.4 ± 6.9 16.3 ± 6.1
16.2 ± 5.8 15.0 ± 3.9
16.8 ± 5.5 13.5 ± 4.5
18.7 ± 6.2 18.1 ± 5.4
19.0 ± 7.1 18.0 ± 6.8
19.2 ± 7.2 17.4 ± 6.5
20.1 ± 7.2 18.8 ± 6.8
18.4 ± 1.4 16.7 ± 1.9
<0.0001 <0.0001
29.7 ± 8.5 22.6 ± 9.3
21.0 ± 6.4 18.6 ± 5.4
27.4 ± 10.2 24.5 ± 7.2
28.3 ± 9.4 24.0 ± 8.0
21.5 ± 6.4 19.0 ± 5.3
18.3 ± 6.4 19.9 ± 5.2
26.8 ± 12.5 25.7 ± 10.3
23.8 ± 9.2 20.4 ± 8.9
24.6 ± 4.1 21.8 ± 2.7
0.0022 0.0012
rmal group.
p.
Fig. 3. Magnocellular layer 1: Box plots for dendrite complexity (A) and dendrite length (B) in the normal group, and vehicle-treated (VT) and memantine-treated (MT)
glaucoma groups. Compared to normal group, dendrite complexity and dendrite length were reduced in VT glaucoma group. Dendrite complexity and dendrite length in MT
group were signiﬁcantly increased compared to VT group (P = 0.0048 and P = 0.0022, respectively). The box extends from the 25th percentile to the 75th percentile, with
horizontal solid line and square at the median and mean, respectively. The bars indicate the highest and lowest values determined by the 25th and 75th percentiles.
Fig. 4. Parvocellular layer 6: Box plots for dendrite complexity (A) and dendrite length (B) in the normal group, and VT and MT glaucoma groups. Compared to normal group,
dendrite complexity and dendrite length were reduced in VT glaucoma group. Dendrite complexity and dendrite length in MT glaucoma group were signiﬁcantly increased
compared to VT glaucoma group (P = 0.0011; P = 0.0012, respectively). The box extends from the 25th percentile to the 75th percentile, with horizontal solid line and square
at the median and mean, respectively. The bars indicate the highest and lowest values determined by the 25th and 75th percentiles.
Table 2
Dendrite complexity and total dendrite length of vehicle-treated and memantine-treated glaucoma monkeys.
Group, ID Decrease in dendrite complexity (%) Mean Decrease in total dendrite length (%) Mean
Layer 1 Layer 6 Layer 1 Layer 6
Vehicle-treated
91 51.9 48.6 52.2 51.6
92 59.9 55.2 57.9 55.5
93 55.3 55.7 56.4 59.9
96 55.7 49.5 51.4 46.3
98 50.6 41.5 50.6 46.6
105 48.5 44.8 50.1 48.4
106 48.5 39.6 47.8 44.2
Mean ± SD 52.9 ± 4.2 47.8 ± 6.3 52.4 ± 3.6 50.4 ± 5.7
Memantine-treated
94 23.2 31.1 22.9 32.9
95 49.4 40.6 45.5 44.8
97 34.2 31.6 28.8 27.3
99 30.8 28.3 26.5 28.8
100 43.5 39.6 44.2 43.6
101 55.3 41.0 52.5 40.9
102 30.0 22.2 30.4 23.7
107 38.8 35.8 38.2 39.5
Mean ± SD 38.1 ± 10.7 33.8 ± 6.7 36.1 ± 10.5 35.2 ± 8.1
P value 0.0047 0.0011 0.0019 0.0011
SD = Standard deviation.
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Fig. 5. Magnocellular layer 1: Plots of percent dendrite complexity reduction (A) and percent dendrite length reduction (B) as a function of mean IOP. Triangles and circles
indicate percent decrease in dendrite complexity in MT and VT glaucoma group, respectively. (A) Dotted and solid lines represent linear ﬁt and 95% conﬁdence intervals for
the MT and VT glaucoma groups, respectively. Percent decrease in dendrite complexity increased with elevated mean IOP. Similar results were obtained when percent
dendrite length reduction was assessed (B).
Fig. 6. Parvocellular layer 6: Plots of percent dendrite complexity reduction (A) and percent dendrite length reduction (B) as a function of mean IOP. Triangles and circles
indicate percent decrease in dendrite complexity in MT and VT glaucoma group, respectively. (A) Dotted and solid lines represent linear ﬁt and 95% conﬁdence intervals for
the MT and VT glaucoma groups, respectively. Percent decrease in dendrite complexity increased with elevated mean IOP. Similar results were obtained when percent
dendrite length reduction was assessed (B).
248 T. Ly et al. / Vision Research 51 (2011) 243–250VT group (P = 0.0003). The linear regression of the dendrite length
decrease on IOP was statistically signiﬁcant (Fig. 6B) (P < 0.05). AN-
COVA test, with mean IOP as a covariate, showed signiﬁcantly less
percent decrease in dendrite length in the MT compared to the VT
group in parvocellular layer 6 (P = 0.0061).4. Discussion
Pathologic changes in dendrites are considered an early sign of
neuron injury (Bywood & Johnson, 2000) and the decrease in
MAP2-immunostained dendrites is considered an early indicator
of neuron injury (Kitagawa et al., 1989; Kwei et al., 1993). Den-
drites of relay LGN neurons in normal primate have been rarely
studied (Wilson, 1986, 1989), and no detailed quantitative assess-
ment of dendritic parameters are available. A previous study in
experimental primate glaucoma with mild optic nerve ﬁber loss,
showed reduction of dendritic complexity and ﬁeld area in the
LGN neurons without distinguishing larger relay neurons from
smaller interneurons (Gupta et al., 2007). The combination of dou-
ble labeling with MAP2, a dendritic marker and parvalbumin, a cell
type speciﬁc marker for relay LGN neurons (Johnson & Casagrande,
1995), with confocal microscopy and 3D reconstruction/tracing en-
abled us to perform the quantitative assessment of dendrites of
LGN relay neurons in glaucomatous monkeys in comparison withnormal monkeys. This study shows for the ﬁrst time a decrease
in dendrite complexity and in length of speciﬁcally the relay LGN
neurons in primate glaucoma. Furthermore, this analysis showed
that both dendrite complexity and length of relay LGN neurons
in glaucoma decreased with mean IOP. Further studies are needed
to determine the functional signiﬁcance of dendritic changes in
surviving relay LGN neurons, and their involvement in visual dys-
function in glaucoma. Recent studies in retinae of primate glau-
coma showed that retinal ganglion cells were less responsive,
both spatially and temporally, to visual stimuli, and that the reduc-
tion in visual responsiveness most likely results from signiﬁcant
changes in dendritic architecture (Weber & Harman, 2005).
Blockade of NMDA open channel receptor using memantine
attenuated decrease in dendrite complexity and in length in relay
LGN neurons in primate glaucoma. Conﬁrmation of these results
by ANCOVA analysis using mean IOP as covariate, suggests that the
difference between memantine-treated and vehicle-treated groups
is not due to differences in mean IOP between groups. Memantine
also protected cell body size in the LGN in glaucoma (Yucel, Gupta
et al., 2006) and thismay be in part due to action onNMDA receptors
in relay LGN neurons (Jones, Tighilet, Tran, & Huntsman, 1998).
Memantine may also be acting on the NMDA receptor subtype lo-
cated in the retina (Grunert, Haverkamp, Fletcher, & Wassle, 2002)
and the visual cortex (Huntley et al., 1994), each major sources of
excitatory input to the LGN (Montero &Wenthold, 1989). Although
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increased in LGN layer in primate glaucoma (Yucel, Darabie, Wang,
Kaufman, & Gupta, 2006), the expression of other NMDAR subunits
(Liu et al., 2007) and the cellular location of NMDARs (synaptic or
extrasynaptic) (Hardingham, Fukunaga, & Bading, 2002; Sattler,
Xiong, Lu,MacDonald,&Tymianski,2000) thatare implicated incon-
trolling their effect on neuronal viability, are not yet known in nor-
mal and glaucomatous LGN. This knowledge may be important to
understand the effect of memantine of relay neurons in glaucoma-
tous LGN since memantine has been shown to act preferentially on
the extrasynaptic NMDA receptors (Leveille et al., 2008). It is not
clear whether the extent of dendritic changes followingmemantine
treatment contributes the decrease in amplitude reduction of visu-
ally-evokedcorticalpotential inmemantine-treatedglaucomamon-
keys (Hare et al., 2004). Memantine failed to demonstrate a
neuroprotective treatment effect on visual ﬁelds of glaucoma pa-
tients in a large clinical trial. Nonetheless, the ﬁnding of measurable
dendrite plasticity in central visual neurons following administra-
tion ofmemantine suggests that targeting LGNneurons in glaucoma
is a strategy worth exploring to prevent visual dysfunction in
glaucoma.
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